REFERENCES
  1. National Institute of Infectious Diseases. [in Japanese] Infect Agents Surveil Report. 2019; 40: 192-194.
  2. The Ministry of Health, Labour and Welfare. The treatment guidelines for adults of novel influenza. https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/infulenza/dl/guideline.pdf Accessed June 6, 2020.
  3. The Japanese Respiratory Society. The influenza internet surveillance system. [in Japanese] https://www.jrs.or.jp/iis/ Accessed June 6, 2020.
  4. The Japanese Respiratory Society. The JRS guidelines for management of pneumonia in adults. [in Japanese] The Japanese Respiratory Society, Tokyo, 2017.
  5. Abdel-Hady, Balushi, RM, Abri BA, et al. Estimating the burden of influenza-associated hospitalization and death in Oman (2012-2015). Influenza Other Respir Viruses 2018; 15: 146-152.
  6. Palekar RS, Rolfes MA, Arriola CS, et al. Burden of influenza-associated respiratory hospitalizations in Americas, 2010-2015. PloS One 2019 Sep 6; 14(9): 0221479. doi: 10.1371/journal.pone.0221479.
  7. Ng Y, Chua LAV, Ma S, Lee VJM. Estimates of influenza-associated hospitalizations in tropical Singapore, 2010-2017: higher burden estimated in more recent years. Influenza Other Respir Viruses 2019; 13: 574-581.
  8. Ao T, McCracken JP, Lopez MR, et al. Hospitalization nd death among patients with influenza, Guatemala, 2008-2012. BMC Public Health 2019 May 10; 19 (Suppl 3):463. doi: 10.1186/s12889-019-6781-6.
  9. Pivette M, Nicolay N, de Lauzun V, Hubert B. Characteristics of hospitalization with an influenza diagnosis, France, 2012-2013 to 2016-2017 influenza seasons. Influenza Other Respir Viruses 2020; 14: 340-348.
  10. Moa AM, Muscatello DJ, Turner RM, Maclntyre CR. Estimated hospitalizations attributable to seasonal and pandemic influenza in Australia: 2001-2013. PloS One 2020 Apr 13; 15(4):e0230705. doi: 10.1371/journal.pone.0230705.
  11. Yokomichi H, Mochizuki M, Lee JJ, Kojima R, Yokoyama T, Yamagata Z. Incidence of hospitalization for severe complications of influenza virus infection in Japanese patients between 2012 and 2016: a cross-sectional study using routinely collected administrative data. BMJ Open 2019 Jan 17; 9(1):e024687. doi: 10.1136/bmjopen-2018-024687.
  12. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-1340.
  13. Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011; 52: S75-S82.
  14. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-1902.
  15. Maruyama T, Fujisawa T, Suga s, et al. Outcome and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy. Chest 2016; 149: 526-534.
  16. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016; 62: 817-823.
  17. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016; 10: 394-403.
  18. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68: e1-e47.
  19. The Ministry of Health, Labour and Welfare. Age distribution of fatal cases dueb to 2009 pandemic influenza A (H1N1) in Japan https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/rireki/100331-03.html Accessed June 6, 2020.
  20. Sugaya N, Shinjoh M, Mitamura K, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza in children. Clin Infect Dis 2008; 47: 339-345.
  21. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother 2011; 17: 595-601.
  22. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. 2018; 379: 913-923.
  23. Ison MG, Postmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020 Jun 8; S1473-3099(20)30004-9. doi: 10.1016/S1473-3099(20)30004-9.
  24. Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2020; 221: 346-355.
  25. Yoshimura Y, Sasaki H, Horiuchi H, et al. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan. Eur J Clin Microbiol Infect Dis 2020 Apr 14. doi: 10.1007/s10096-020-03888-7.
  26. Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada. Vaccine 2008; 26: 4697-4703.
  27. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510-515.
  28. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011; 52: 301-312.
  29. Moser JS, Galindo-Fraga A, Ortiz-Hernández AA, et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir Viruses 2019; 13: 3-9.